첨단바이오 포커스

국민의 안전과 건강을 지키는 한국의약품안전관리원

홈 > 알림마당 > 뉴스레터 > 첨단바이오 포커스

인쇄
게시글 보기
제목 첨단바이오 포커스 제6호
등록자 hyj0117 등록일 2021-06-03 조회수 486






Reference

1. 식품의약품안전처 홈페이지 Available from: https://www.mfds.go.kr/brd/m_218/view.do?seq=33379

2. 식품의약품안전처 홈페이지 Available from: https://www.mfds.go.kr/brd/m_1059/view.do?seq=14843&srchFr=&srchTo=&srchWord=&srchTp=&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&page=1

3. 식품의약품안전처 홈페이지 Available from: https://www.mfds.go.kr/brd/m_1059/view.do?seq=14844&srchFr=&srchTo=&srchWord=&srchTp=&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&page=1

4. 보건복지부 홈페이지 Available from: http://www.mohw.go.kr/react/al/sal0301vw.jsp?PAR_MENU_ID=04&MENU_ID=0403&page=2&CONT_SEQ=365315

5. 보건복지부 홈페이지 Available from: http://www.mohw.go.kr/react/al/sal0301vw.jsp?PAR_MENU_ID=04&MENU_ID=0403&page=1&CONT_SEQ=365427

6. 한국바이오인력개발센터 Available from: https://bioexpert.kbiohealth.kr/fro_end/html/dep_04/4100.php?pagetype=&rownum=1&bbs_idx=360&pageno=1&pagekind=c&bbsid=notice&cafeid=&ref_code=&keyword=&keyfield=&category=&qstr=&gopage=/fro_end/html/dep_04/4100.php?

7. “Workshop: Patient Engagement & Regenerative Medicine: An FDA CBER Workshop for Patient Advocates” US FDA. Accessed Apr 6, 2021 Available from: https://www.fda.gov/vaccines-blood-biologics/workshops-meetings-conferences-biologics/patient-engagement-regenerative-medicine-fda-cber-workshop-patient-advocates-05062021-05062021

8. “CBER Regenerative Medicine Advanced Therapy (RMAT) Designations Withdrawn after Granting or Rescinded by Fiscal Year” US FDA. Accessed Apr 5, 2021 Available from: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/cumulative-cber-regenerative-medicine-advanced-therapy-rmat-designation-requests-received-fiscal

9. “Biological Product and HCT/P Deviation Reports – Annual Summary for Fiscal Year 2020” US FDA. Accessed Apr 8, 2021 Available from: https://www.fda.gov/media/147441/download

10. “Guidance Agenda: Guidance Documents CBER is Planning to Publish During Calendar Year 2021” US FDA. Accessed Apr 12, 2021 Available from: https://www.fda.gov/vaccines-blood-biologics/biologics-guidances/guidance-agenda-guidance-documents-cber-planning-publish-during-calendar-year-2021

11. “PUBLIC: Model Informed Drug Development Approaches for Immunogenicity Assessments” US FDA. Accessed Apr 23, 2021 Availaboe from: https://www.fda.gov/news-events/fda-meetings-conferences-and-workshops/model-informed-drug-development-approaches-immunogenicity-assessments-06092021-06092021

12. “Summary Basis for Regulatory Action” US FDA. Accessed Apr 16, 2021 Available from: https://www.fda.gov/media/147627/download

13. “Exceptions and Alternative Procedures Approved Under 21 CFR 640.120” US FDA. Accessed Apr 21, 2021 Available from: https://www.fda.gov/vaccines-blood-biologics/regulation-blood-supply/exceptions-and-alternative-procedures-approved-under-21-cfr-640120

14. “Guidance Document: Nonclinical Testing of Individualized Antisense Oligonucleotide Drug Products for Severely Debilitating or Life-Threatening Diseases Guidance for Sponsor-Investigators” US FDA. Accessed Apr 26, 2021 Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonclinical-testing-individualized-antisense-oligonucleotide-drug-products-severely-debilitating-or

15. “Committee for Advanced Therapies (CAT): work-plan-Apr” EMA. Accessed Apr. 14, 2021 Available from: https://www.ema.europa.eu/en/documents/agenda/agenda-cat-agenda-14-16-april-2021-meeting_en.pdf

16. “What’s new” EMA. Accessed Apr. 2021 Available from: https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/advanced-therapies/advanced-therapy-classification/scientific-recommendations-classification-advanced-therapy-medicinal-products

17. “recommendations eligibility prime scheme adopted CHMP meeting Apr 2021” EMA.

Accessed Apr. 2021 Available from: https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibilit

y-prime-scheme-adopted-chmp-meeting-19-22-april-2021_en.pdf

18. “Orphan designations-eu3141296” EMA. Accessed Apr. 09. 2021 Available from: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3141296

19. “Orphan designations-eu3161760” EMA. Accessed Apr. 09. 2021 Available from: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3161760

20. “Orphan designations-eu3182033” EMA. Accessed Apr. 29. 2021 Available from: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3182033

21. “Kymriah” EMA. Accessed Apr. 07, 2021 Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/kymriah

22. 국가암정보센터 홈페이지 Available from: https://www.cancer.go.kr/lay1/program/S1T211C223/cancer/view.do?cancer_seq=114462

23. “Fabrazyme” EMA. Accessed Apr. 23, 2021 Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/fabrazyme

24. “Tevagrastim ” EMA. Accessed Apr. 26, 2021 Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/tevagrastim

25. “Nivestim” EMA. Accessed Apr. 29, 2021 Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/nivestim

26. “CPhI Japan celebrates return” Cleanroom technology. Accessed Apr. 28, 2021 https://www.cleanroomtechnology.com/news/article_page/CPhI_Japan_celebrates_return/176259

27. “Japan invents novel cell therapy for type I diabetes mellitus” Biospectrum. Accessed Apr. 16, 2021 https://www.biospectrumasia.com/news/98/17990/japan-invents-novel-cell-therapy-for-type-i-diabetes-mellitus.html

28. Dussiux D, Arber W. Host specificity of DNA produced by Escherichia coli. II. Control over acceptance of DNA from infecting phage lambda. J. Mol. Biol. 1962 Jul;5:37-49.

29. 노벨위원회 보도자료Available from: https://www.nobelprize.org/prizes/medicine/1978/summary/

30. 식품의약품안전평가원유전자 가위기술 연구개발 동향보고서. 2017. Available from: https://www.nifds.go.kr/brd/m_18/view.do?seq=11003&srchFr=&srchTo=&srchWord=&srchTp=&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&page=17

31. 노벨위원회 보도자료 Available from: https://www.nobelprize.org/prizes/chemistry/2020/summary/

32. Adli M. The CRISPR tool kit for genome editing and beyond. Nat. Commun. 2018 May 15;9(1):1911.

33. 한국분자·세포생물학회 홈페이지유전체 교정을 위한 유전자가위 (engineered nuclease) 의 개발과 활용. 2013 Available from: https://www.ksmcb.or.kr/board/list.html?num=3551&start=0&sort=top%20desc,pos%20asc,num%20desc&code=bbs11&period=&&title=01&key=subject_body&keyword=%B0%A1%C0%A7

34. 한국과학기술연구원 (KIST) 융합연구정책센터 홈페이지유전자 편집기술. 2016. Available from: https://crpc.kist.re.kr/user/nd8407.do?View&boardNo=00005736

35. 질병관리청 홈페이지새로운 유전체 편집 기술이 실험실 생물안전에 미치는 영향 고찰. 2017.

Available from: http://kdca.go.kr/board/board.es?mid=a20602010000&bid=0034&act=view&list_no=76004

36. Gupta RM, Musunuru K. Expanding the genetic editing tool kit: ZFNs, TALENs, and CRISPR-Cas9. J. Clin. Invest. 2014 Oct 1; 124(10): 41544161.

37. Cox DBT, Platt RJ, Zhang F. Therapeutic genome editing: prospects and challenges. Nat. Med. 2015 Feb;21(2):121-31.

38. Li H et al., Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects. Signal Transduct Target Ther. 2020 Jan 3;5(1):1.

39. 한국보건산업진흥원 홈페이지희귀난치 질환 치료를 위한 유전자 교정 치료제 개발동향. 2017. Available from: https://www.khidi.or.kr/board/view?linkId=222045&menuId=MENU01435

40. Kim D et al., Genome-wide analysis reveals specificities of Cpf1 endonucleases in human cells. Nat. Biotechnol. 2016 Aug;34(8):863-8.

41. Batra R et al., Elimination of Toxic Microsatellite Repeat Expansion RNA by RNA-Targeting Cas9. Cell. 2017 Aug 24;170(5):899-912.e10.

42. Cox DBT et al., RNA editing with CRISPR-Cas13. Science. 2017 Nov 24;358(6366):1019-1027.

43. Abudayyeh O et al., A cytosine deaminase for programmable single-base RNA editing. Science. 2019 Jul 26;365(6451):382-386.

44. Anzalone AV et al., Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 2019 Dec;576(7785):149-157.

45. Mullard A. Gene-editing pipeline takes off. Nat Rev Drug Discov. 2020 Jun;19(6):367-372.

46. 생명공학정책연구센터 홈페이지생체 내 유전체 편집기술. 2018. Available from: https://www.bioin.or.kr/board.do?num=279290&cmd=view&bid=report

47. 생물학연구정보센터 홈페이지샤르코-마리-투스병(Charcot-Marie-Tooth disease)에 대한 이해와 연구 동향. 2020. Available from: https://www.ibric.org/myboard/read.php?Board=report&id=3621&Page=1&PARA9=1

48. Lee J et al., Targeted PMP22 TATA-box editing by CRISPR/Cas9 reduces demyelinating neuropathy of Charcot-Marie-Tooth disease type 1A in mice. Nucleic Acids Res. 2020 Jan 10;48(1):130-140.

49. Cho SW et al., Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases. Genome Res. 2014 Jan;24(1):132-41.

50. Park J et al., Digenome-seq web tool for profiling CRISPR specificity. Nat Methods. 2017 May 30;14(6):548-549.

51. Naeem M et al., Latest Developed Strategies to Minimize the Off-Target Effects in CRISPR-Cas-Mediated Genome Editing. Cells. 2020 Jul 2;9(7):1608.

52. Charlesworth CT et al., Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nat Med. 2019 Feb;25(2):249-254.

53. SSEIM (Society for the Study of Inborn Errors of Metabolism, 선천성 대사장애 연구학회홈페이지연례미팅에서 발표된 초기 임상시험 결과. 2018.

Available from: https://d1io3yog0oux5.cloudfront.net/_e88d11c13f3d44ad083f6421f79b50e4/sangamo/db/240/1488/pdf/09.05.18+Muenzer+SB-

913-1602+SSIEM+2018+FINAL.pdf 


첨부파일
첨단바이오 포커스 제6호 _21년 6월.pdf [27017415 byte]